| dc.description.abstract | Nanozymes, artificial nanomaterials mimicking enzyme activity, are at the forefront of
innovative cancer therapies, particularly in chemodynamic therapy (CDT), photodynamic
therapy (PDT), and photothermal therapy (PTT). Their capacity to selectively generate reactive
oxygen species under tumor-specific conditions, including low pH and high H₂O₂ levels,
facilitates targeted induction of cancer cell death while minimizing damage to healthy tissues.
When integrated with PDT or PTT, nanozymes enhance oxidative stress and promote
immunogenic cell death, further amplifying anti-tumor immune responses. Recent advances in
single-atom nanozymes and intelligent nanozymes have shown promise in overcoming
therapeutic limitations, such as tumor hypoxia and immune suppression while modulating the
tumor microenvironment to boost treatment efficacy. Additionally, ongoing preclinical and
clinical evaluations highlight the potential of nanozymes to synergistically enhance
immunotherapy outcomes. Their advantages over traditional enzymes, such as stability,
tunability, cost-effectiveness, and the ability to maintain catalytic activity in hostile
environments, position nanozymes as transformative agents in cancer therapy. However, their
clinical translation faces significant challenges, including biocompatibility concerns, delivery
inefficiencies to tumor sites, and stringent regulatory hurdles, which require comprehensive
research and innovative solutions to address. Despite these limitations, advancements in
nanozyme design and functionalization continue to pave the way for more effective and safer
applications in cancer therapy which will be discussed in detail in this review. | en_US |
